Results 231 to 240 of about 28,422 (269)

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study

Journal of Allergy and Clinical Immunology: in Practice, 2019
BACKGROUND Omalizumab has demonstrated efficacy in clinical trials of patients with asthma, but real-world data are needed. OBJECTIVE To assess outcomes after omalizumab initiation in patients with asthma in a real-world setting.
Thomas B Casale, William W Busse, Robert S Zeiger   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria

International Archives of Allergy and Immunology, 2023
Introduction: Chronic urticaria (CU) is a common skin condition that can be divided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).
Rentao Yu, W. Qian, Q. Zheng, Jianxian Xiong, Shuang Chen, Aijun Chen, Jin Chen, S. Fang, Kun Huang, T. Cai   +9 more
semanticscholar   +1 more source

Omalizumab

Reactions Weekly, 2018
  +9 more sources

The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Omalizumab is a newly FDA approved anti-IgE therapy for allergen agnostic treatment of single or multiple food allergies in patients ages >1 year.
M. Shaker, A. Anagnostou, E. Abrams, Michael W Lee, Alexandra E. Conway, Karen S. Hsu Blatman, J. Oppenheimer, M. Greenhawt   +7 more
semanticscholar   +1 more source

Omalizumab Safety Concerns.

Journal of Allergy and Clinical Immunology
IgE and mast cells play key roles in the pathophysiology of allergic diseases, and omalizumab was the first monoclonal anti-IgE antibody licensed in the U.S. when initially FDA-approved for the treatment of allergic asthma in 2003.
T. Pongdee, James T. Li
semanticscholar   +1 more source

A Practical Guide for Implementing Omalizumab Therapy for Food Allergy.

Journal of Allergy and Clinical Immunology
The recent approval of omalizumab for the treatment of IgE-mediated food allergy is an important step forward for the millions of food allergy patients in the US.
Thomas B. Casale, A. Fiocchi, M. Greenhawt   +2 more
semanticscholar   +1 more source

Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis

International Archives of Allergy and Immunology, 2021
Introduction: Compared with the placebo, biologics are beneficial in reducing nasal polyp mass and safe in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, there lacks a head-to-head randomized trial comparing biologics. We aimed
Qingwu Wu, Yana Zhang, W. Kong, Xinyue Wang, Lianxiong Yuan, R. Zheng, H. Qiu, Xue-kun Huang, Qintai Yang   +8 more
semanticscholar   +1 more source

Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.

JAMA dermatology
Importance Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are ...
R. Soegiharto, M. Alizadeh Aghdam, J. Sørensen, E. van Lindonk, F. Bulut Demir, Nasser Mohammad Porras, Y. Matsuo, L. Kiefer, A. Knulst, Marcus Maurer, C. Ritchie, M. Rudenko, E. Kocatürk, R. Criado, S. Gregoriou, T. Bobylev, A. Kleinheinz, S. Takahagi, M. Hide, A. Giménez-Arnau, A. Salman, R. Kara, B. Sevimli Dikicier, M. V. van Doorn, S. Thomsen, J. M. Van den Reek, H. Röckmann   +26 more
semanticscholar   +1 more source

The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology.

Journal of Allergy and Clinical Immunology
Omalizumab was recently approved by the US Food and Drug Administration for treatment of any single food allergy or multiple food allergies in children aged 1 year and older and adults.
MD Aikaterini Anagnostou, MD J. Andrew Bird, MD Sharon Chinthrajah, MD Timothy E. Dribin, MD David M. Fleischer, MD Edwin Kim, MD Anna Nowak-Wegrzyn, MD Rima Rachid, MD MS Marcus S. Shaker, MD Wayne Shreffler, MD Scott Sicherer, MD Jonathan Tam, MD Brian P. Vickery, M. M. M. Yamini V. Virkud, MD Julie Wang, MD Michael Young, MD Mba MSc Matthew Greenhawt   +16 more
semanticscholar   +1 more source

Omalizumab

Reactions Weekly, 2019
  +8 more sources